Life-years and quality-adjusted life-years with belantamab mafodotin, bortezomib, and dexamethasone vs alternative regimens in patients with Relapsed/Refractory multiple myeloma who received ≥1 prior line of therapy
Analysis shows improved life-years and QALYs with belantamab mafodotin in relapsed multiple myeloma, indicating its efficacy over alternative therapies.
Key Points
To compare the long-term life-years and quality-adjusted life-years for belantamab mafodotin versus alternative therapies in relapsed/refractory multiple myeloma.
Developed a partitioned survival model comparing belantamab mafodotin to proteasome inhibitors, starting at age 64.
Estimated lifetime outcomes using a time horizon of 36 years for life-years and QALYs.
Utilized data from the DREAMM-7 trial for efficacy and EQ-5D-3L for health state utilities.
Belantamab mafodotin resulted in an average of 12.0 life-years and 9.8 QALYs.
Higher estimated probability of survival at 5 years for belantamab mafodotin (64%) compared to alternatives (34% to 53%).
Outperformed alternative therapies such as carfilzomib, daratumumab, and others in both LYs and QALYs.
Cite This Study
Suvannasankha et al. (2025) studied this question.